Join
Live feed
·
PRReleasevia Quantisnow
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

ByQuantisnow·Wall Street's wire, on your screen.
CMMB· Chemomab Therapeutics Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CMMB (Chemomab Therapeutics Ltd.) and more on Quantisnow.